Compare DexCom, Inc. (DXCM) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Robinhood Markets, Inc. — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Robinhood Markets, Inc. trades at $109.1 (market cap $96.21B). The key difference: Robinhood Markets, Inc. is far larger — about 3× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Robinhood Markets, Inc. for 75 Days on average.
| DXCM | HOOD | |
|---|---|---|
Market Cap | $31.86B | $96.21B |
Volume | 3,607,070 | 22,572,153 |
Sector | Health | Financials |
52-Week High | $92.34 | $152.46 |
52-Week Low | $54.84 | $65.16 |
Typical Hold Time | 62 Days | 75 Days |
Enterprise Value | $31.32B | $102.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Robinhood (HOOD) trades at $109.02, down 0.45% on the day, with a bullish technical signal and strong support at $105. The company reported robust 2025 results with revenue of $4.47B and net income of $1.88B, though valuation ratios like a P/E of 47.35 remain elevated. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at driving growth.
The outlook is positive with a consensus price target of $137.53, implying 26% upside, supported by analyst optimism and product innovation. Key risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny over new offerings like leveraged crypto trading, which could impact investor sentiment and stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
